Kenya vs Ukraine: Average cost of drugs for extensively drug-resistant tuberculosis
Kenya
1,800 constant 2022 US$
in 2024
Ukraine
1,566 constant 2022 US$
in 2024
Kenya rank
29th
Ukraine rank
31st
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Kenya
- Ukraine
How they compare
Kenya currently reports 1,800 constant 2022 US$ against 1,566 constant 2022 US$ in Ukraine, a difference of 234 constant 2022 US$.
That makes Kenya's figure about 1.1 times Ukraine's.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Ukraine ahead.
Kenya ranks 29th and Ukraine ranks 31st of 56 countries.
Ukraine has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kenya | Ukraine | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,500 constant 2022 US$ | 5,398 constant 2022 US$ | 897.67 constant 2022 US$ | Ukraine |
| 2020s | 2,706 constant 2022 US$ | 3,686 constant 2022 US$ | 980 constant 2022 US$ | Ukraine |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Kenya or Ukraine?
- Kenya, at 1,800 constant 2022 US$ against 1,566 constant 2022 US$ in Ukraine as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Kenya and Ukraine?
- 234 constant 2022 US$, with Kenya ahead.
- How many years of comparable data are there for Kenya and Ukraine?
- 8 years are reported by both, from 2017 to 2024.
- How do Kenya and Ukraine rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Kenya ranks 29th and Ukraine ranks 31st of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.